L name

Manufactured by Merck Group

Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, France, Brazil, Italy, Belgium, China, Canada, Spain

L-NAME is a synthetic compound that functions as a nitric oxide synthase inhibitor. It is commonly used in research applications to study the role of nitric oxide in biological processes.

Automatically generated - may contain errors

Lab products found in correlation

Indomethacin, by Merck Group (57 mentions) Acetylcholine, by Merck Group (34 mentions) Phenylephrine, by Merck Group (32 mentions) L arginine, by Merck Group (26 mentions) Sodium nitroprusside, by Merck Group (24 mentions) Acetylcholine chloride, by Merck Group (17 mentions) Glibenclamide, by Merck Group (17 mentions) Dimethyl sulfoxide (dmso), by Merck Group (14 mentions) Carbachol, by Merck Group (11 mentions) U46619, by Merck Group (10 mentions) Ng nitro l arginine methyl ester, by Merck Group (9 mentions) Methylene blue, by Merck Group (9 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (9 mentions) Phenylephrine hydrochloride, by Merck Group (8 mentions) Propranolol, by Merck Group (8 mentions) Apamin, by Merck Group (8 mentions) Potassium chloride (kcl), by Merck Group (8 mentions) Apocynin, by Merck Group (7 mentions) Cptio, by Merck Group (7 mentions) Ascorbic acid, by Merck Group (7 mentions)

Spelling variants of this product

471 protocols using l name

Depo Dose and Treatment Study

Check if the same lab product or an alternative is used in the 5 most similar protocols

Dose study. To detect the appropriate dose of Depo (Aranesp; AMGEN, Thousand Oaks, CA, USA) we randomly divided 60 female adult rats into 6 groups: L-NAME (20 mg/kg/day; Sigma Aldrich, St. Louis, MO, USA) alone, L-NAME + 0.1 µg/kg Depo, L-NAME + 0.25 µg/kg Depo, L-NAME + 0.5 µg/kg Depo, L-NAME + 2.5 µg/kg Depo, and L-NAME + 10 µg/kg Depo. Due to the half-life of Depo, it was injected once every 3 days. According to the survival and blood parameters, 0.25 µg/kg Depo was determined as the highest dose that did not change the blood parameters and was used as the treatment dose throughout the rest of the study (Table 1).
Treatment study. We randomly separated 60 female adult rats into 6 groups and we injected the study drugs for 30 days: Control (1 mL/kg/day saline); L-NAME (20 mg/kg/day); L-NAME (20 mg/kg/day) + Depo (0.25 µg/kg once every 3 days); L-NAME (20 mg/kg/day) + Rem (5 mg/kg/day infliximab [Inf]; Janssen Biotech, Inc., Horsham, PA, USA); L-NAME (20 mg/kg/day) + Depo (0.25 µg/kg once every 3 days) + Rem (5 mg/kg/day); and Depo (0.25 µg/kg once every 3 days).

Ozkurt M., Uzuner K., Erkasap N., Kus G., Ozyurt R., Uysal O., Akyazi I, & Kutlay O. (2018). Erythropoietin Protects the Kidney by Regulating the Effect of TNF-α in L-NAME-Induced Hypertensive Rats. Kidney & blood pressure research, 43(3).

+ Open protocol

+ Expand

Melatonin and L-NAME Effects on Pinealectomized Rats

Check if the same lab product or an alternative is used in the 5 most similar protocols

The animal experiments of this research was performed in the laboratories of Canakkale Onsekiz Mart University Experimental Research Center (COMUDAM). Animals were maintained from COMUDAM and used with the approval of the Canakkale Onsekiz Mart Uni-versity Animal Care and Use Local Ethics Committee (2013/02 -13) .
In this study, we used 42 Sprague Dawley male adult rats weighing 200-250 g. Animals were housed according to 12-h light-dark cycle and 22 ˚C room temperature. All rats fed ad libitum, and the groups are designed after recording the weights and blood pressure values.
-SHAM group (n=7) rats were SHAM operated.
-SHAM+L-NAME group (n=7) rats were SHAM operated and L-NAME (CAS 51298-62-5: NL'-nitro-L-arginin metil ester, Sigma-Aldrich) was added to the drinking water (40 mg/kg/day).
-PLT group (n=7) rats were pinealectomised.
-PLT+L-NAME group (n=7) rats were pinealectomised and L-NAME was added to the drinking water (40 mg/kg/day).
-PLT+MEL group (n=7) rats were pinealectomised and melatonin was injected subcutanously (sc, S 4858937 244, MERCK; 5 mg/kg/day, at 10 am).
-PLT+L-NAME+MEL group (n=7) rats were pinealectomised, L-NAME was added to the drinking water (40 mg/kg/day) and melatonin was injected sc (5 mg/ kg/day).

Ovali M.A, & Uzun M. (2017). The effects of melatonin administration on KCNQ and KCNH2 gene expressions and QTc interval in pinealectomised rats. Cellular and molecular biology (Noisy-le-Grand, France), 63(3).

+ Open protocol

+ Expand

Nicotinamide and L-NAME Effects in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

WT mice were randomly enrolled into four groups: 1) control: mice received only vehicle (water), 2) Nam: mice were administered with Nam (#72340, Sigma) at a dose of 500 mg/kg/day in drinking water (0.3% weight/volume) [8 ], 3) L-NAME : mice were treated with L-NAME (#483125, Sigma) at dose of 50 mg/kg/day in drinking water (0.03% weight/volume) [14 (link)], 4) L-NAME + Nam: mice were treated with both L-NAME and Nam via drinking water at dose described in 2) and 3) respectively. After 2 months treatment, mice were euthanized, and body fluids and tissues were collected for analysis.

Huynh P.K., Wilder J., Hiller S., Hagaman J., Takahashi N., Maeda-Smithies N, & Li F. (2020). Beneficial effects of nicotinamide on hypertensive mice with impaired endothelial nitric oxide function. Journal of experimental nephrology, 1(1), 1-8.

+ Open protocol

+ Expand

Preeclampsia-like Model in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

The preeclampsia-like model was established through the following methods: (1) L-NAME model: L-NAME (Sigma-Aldrich, St. Louis, MO, USA) 50 mg·kg⁻¹·d⁻¹ was administered subcutaneously to pregnant mice from the gestational day 7 to 18 and (2) LPS model: the pregnant mice were injected a single intraperitoneal injection with an ultra-low dose of LPS (Sigma-Aldrich, St. Louis, MO, USA), 1 μg/kg on the gestational day 7. Pregnant mice were simultaneously injected with saline as a normal pregnancy control group (Control). The pregnant mice of each group were randomly divided into two groups treated with normal saline (NS) (L-NAME + NS, LPS + NS, and Control + NS, n = 8) or Pra (Sigma-Aldrich) 5 mg·kg⁻¹·d⁻¹ (L-NAME + Pra, LPS + Pra, and Control + Pra, n = 8) from days 8–18 of gestation by intragastric administration. L-NAME or LPS was injected into nonpregnant mice as the nonpregnant control group (NP-L-NAME and NP-LPS, n = 8).

Huai J., Yang Z., Yi Y.H, & Wang G.J. (2018). Different Effects of Pravastatin on Preeclampsia-like Symptoms in Different Mouse Models. Chinese Medical Journal, 131(4), 461-470.

+ Open protocol

+ Expand

Nicotinamide and L-NAME Effects in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

+ Open protocol

+ Expand

L-NAME-Induced Kidney Injury Model

Check if the same lab product or an alternative is used in the 5 most similar protocols

All animal protocols and procedures were approved by the Bioethics Committee for Animal Research of Instituto Venezolano de Investigaciones Cientificas (IVIC, Caracas — Venezuela). Animals were housed with controlled temperature on a 12/12 h light/dark cycles and maintained on a standard pellet diet and tap water ad libitum.
Male Sprague–Dawley rats weighing 300–350 g, were divided into 3 groups (n = 6 each): L-NAME group, received 70 mg/100 ml of L-NAME (Sigma, St. Louis, MO) in the drinking water; L-NAME + Los group, received L-NAME (70 mg/100 ml), and the oral administration by gastric gavage of Losartan (40 mg/kg/day). Control rats were not treated with L-NAME or Losartan.
L-NAME and Losartan were administered daily for 2 weeks, and then all rats were euthanized under diazepam–ketamine general anesthesia. After renal perfusion with cold saline solution, the kidneys were harvested for immunofluorescence studies (frozen sections), Western blot studies (renal cortical homogenates) and qRT-PCR (RNA later).
Body weight, serum and urine samples were taken weekly. Serum creatinine was determined using an autoanalyzer methodology (Express Plus, Ciba Corning, Oberlin, OH). Urine protein concentration (proteinuria) was determined by the BCA kit (Sigma, St. Louis, MO).

Rincón J., Correia D., Arcaya J.L., Finol E., Fernández A., Pérez M., Yaguas K., Talavera E., Chávez M., Summer R, & Romero F. (2015). Role of Angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension. Life sciences, 124, 81-90.

+ Open protocol

+ Expand

Isoproterenol-Induced Cardiac Hypertrophy Model

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were placed in custom-designed cages fitted with running wheels (China) for a period up to 4 weeks. Mice ran six times a week, the sessions initially lasted for 1.5 h and were increased by 15 min each day to reach 2.5h on day 5. After the exercise-training period, the running wheel was removed from the cage and the mice were allowed to rest for a 24-hour, 1-week, 2-week, or 4-week period. The control (con) and isoproterenol (ISO) groups remained sedentary during the experimental period. Isoproterenol (50 mg/kg) was injected subcutaneously (s.c.) once daily for 8 days. Mice in L-NG-Nitroarginine methyl ester (L-NAME) treatment group were administrated L-NAME (Sigma Aldrich, St. Louis, MO, USA) dissolved in drinking water at a concentration of 100 mg/L during the exercise period (ISO plus exercise plus L-NAME group) or sedentary (ISO plus L-NAME group). Water intake was measured daily by dividing the total consumption by the number of mice in each cage.

Yang L., Jia Z., Yang L., Zhu M., Zhang J., Liu J., Wu P., Tian W., Li J., Qi Z, & Tang X. (2014). Exercise Protects against Chronic β-Adrenergic Remodeling of the Heart by Activation of Endothelial Nitric Oxide Synthase. PLoS ONE, 9(5), e96892.

+ Open protocol

+ Expand

Intravitreal Injections in Ocular Research

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Injections were delivered using a NanoFil-100 syringe with a 26G needle (World Precision Instruments, Sarasota, FL) under isoflurane (0.8% in O_2; IsoThesia; Vetus Animal Health, Rockville Center, NY) inhalation anesthesia at a flow rate of 0.4 L/min using an Isoflurane Anesthesia machine for veterinary use only (Ohmeda Anesthesia Service and Equipment, Inc, Atlanta, GA). Following removal of the occluder, the sclera was exposed by retracting the eyelids with a handmade ocular speculum and injections were delivered through the sclera at the superior margin of the globe, just outside of the scleral ossicles, after cleaning the eyelids and surround area with 70% alcohol. Injections consisted of L-NAME (Sigma Chemical Co, St. Louis, MO) (a 30 μl injection containing 16.2 μmol of L-NAME in 0.9% saline), 30 μl of 0.9% saline (vehicle for L-NAME) (Nickla and Wildsoet, 2004 (link)), atropine sulfate (Sigma Chemical Co) (a 20 μl injection containing 240 nmol of atropine sulfate in phosphate-buffered saline, PBS), and 20 μl of PBS (vehicle for atropine sulfate) (Carr and Stell, 2016 (link)). The needle remained in place for 15 s before slowly withdrawing it from the eye and an ophthalmic antibiotic ointment (Vetropolycin, Pharmaderm, Melvill, NY) was applied to the eye. In some cases, the occluders were replaced prior to awakening from the anesthesia.

Summers J.A, & Martinez E. (2021). Visually induced changes in cytokine production in the chick choroid. eLife, 10, e70608.

+ Open protocol

+ Expand

Murine Model of Heart Failure

Check if the same lab product or an alternative is used in the 5 most similar protocols

Group 1: C57BL/6J (n=5) and group 3: interleukin‐1β^−/− male mice (n=5) were fed a regular chow research diet and considered as control groups. Research Diet for the high‐fat diet (HFD) groups with L‐NAME (50 mg/100 mL, pH 7.4, CAS number: 51298–62‐5, Sigma‐Aldrich) (group 2: C57BL/6J+HFD+L‐NAME [n=5]; group 4: interleukin‐1β^−/−+HFD+L‐NAME [n=5]) was supplied in the drinking water for the 4 months, and these were considered the HFpEF mice. We changed the water with L‐NAME every other day. At the end of the treatment, mice were euthanized using isoflurane (5%) overdose, followed by heart excision when fully sedated.

Srinivas B.K., Bourdi A., O'Regan J.D., Malavalli K.D., Rhaleb N., Belmadani S, & Matrougui K. (2023). Interleukin‐1β Disruption Protects Male Mice From Heart Failure With Preserved Ejection Fraction Pathogenesis. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 12(14), e029668.

+ Open protocol

+ Expand

Chronic L-NAME-induced Hypertension Model

Check if the same lab product or an alternative is used in the 5 most similar protocols

Animal experiments and animal care procedures were approved by the Animal Care Committee of the School of Pharmacy and Biochemistry, University of Buenos Aires (EXP-UBA N°0062949/2015) and were in line with the published Guide for the Care and Use of Laboratory Animals (NIH, 8º Ed., 2011). Animals were maintained on a 12h light/dark cycle in a room at 22 ± 2 ºC with adequate air recycling. All animals were fed standard rodent diet (Asociación Cooperativas Argentinas, Buenos Aires, Argentina) with the following composition (w/w): 20% proteins, 3% fat, 2% fiber, 6% minerals and 69% starch and vitamin supplements, containing the same amount of calories. Male Wistar rats (220-250 g) were treated with L-NAME (Sigma Aldrich, St.
Louis, MO, USA) administered in the drinking water during 8 weeks (30 mg/kg/day).
The dose of L-NAME in the drinking water was selected taking into account that L-NAME reaches a maximal response at 10-15 mg kg/day inducing an increase in BP in the range of 30-40 mmHg [12] . Along with L-NAME intake, animals received 30

Del Mauro J.S., Prince P.D., Donato M., Fernandez Machulsky N., Morettón M.A., González G.E., Bertera F.M., Carranza A., Gorzalczany S.B., Chiappetta D.A., Berg G., Morales C., Gelpi R.J., Taira C.A, & Höcht C. (2017). Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability. Journal of the American Society of Hypertension : JASH, 11(4).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!